Learn key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.
W. David Hardy, MD
Josep M. Llibre, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 439 KB
Released: November 29, 2021
Acknowledgements
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.